4/20
04:18 pm
nuvb
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026 [TheStreet.com]
Low
Report
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026 [TheStreet.com]
4/20
04:05 pm
nuvb
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026
Low
Report
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026
4/17
05:18 pm
nuvb
How Much Can Nuvation Bio (NUVB) Make From Ibtrozi Sales? [Yahoo! Finance]
Low
Report
How Much Can Nuvation Bio (NUVB) Make From Ibtrozi Sales? [Yahoo! Finance]
4/16
11:13 am
nuvb
Nuvation Bio's Ibtrozi Gains Frontline Momentum Ahead of Key Q1 Print, Wedbush Says [Yahoo! Finance]
Medium
Report
Nuvation Bio's Ibtrozi Gains Frontline Momentum Ahead of Key Q1 Print, Wedbush Says [Yahoo! Finance]
4/16
09:47 am
nuvb
Nuvation Bio (NUVB) had its "outperform" rating reaffirmed by Wedbush. They now have a $11.00 price target on the stock.
Low
Report
Nuvation Bio (NUVB) had its "outperform" rating reaffirmed by Wedbush. They now have a $11.00 price target on the stock.
4/14
05:58 am
nuvb
Ibtrozi Prospects Asserts Nuvation Bio Inc. (NUVB) as one of the Best Healthcare Penny Stocks [Yahoo! Finance]
Low
Report
Ibtrozi Prospects Asserts Nuvation Bio Inc. (NUVB) as one of the Best Healthcare Penny Stocks [Yahoo! Finance]
4/7
10:26 am
nuvb
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
Medium
Report
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
4/6
05:38 pm
nuvb
Nuvation Bio Inc. (NUVB) Turns Bullish amid Positive Regulatory Trajectory in Europe [Yahoo! Finance]
Low
Report
Nuvation Bio Inc. (NUVB) Turns Bullish amid Positive Regulatory Trajectory in Europe [Yahoo! Finance]
4/2
01:19 pm
nuvb
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
Low
Report
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
4/2
09:41 am
nuvb
Nuvation Bio (NUVB) had its "outperform" rating reaffirmed by Wedbush. They now have a $11.00 price target on the stock.
Low
Report
Nuvation Bio (NUVB) had its "outperform" rating reaffirmed by Wedbush. They now have a $11.00 price target on the stock.
4/1
08:18 am
nuvb
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo [Yahoo! Finance]
Low
Report
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo [Yahoo! Finance]
4/1
08:00 am
nuvb
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo
Low
Report
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo
4/1
07:21 am
nuvb
Nuvation Bio Inc. (NUVB) and Eisai Get EMA Validation for Taletrectinib [Yahoo! Finance]
Medium
Report
Nuvation Bio Inc. (NUVB) and Eisai Get EMA Validation for Taletrectinib [Yahoo! Finance]
3/27
08:42 am
nuvb
Nuvation Bio (NUVB) had its "outperform" rating reaffirmed by Wedbush. They now have a $11.00 price target on the stock.
Medium
Report
Nuvation Bio (NUVB) had its "outperform" rating reaffirmed by Wedbush. They now have a $11.00 price target on the stock.
3/27
03:18 am
nuvb
Nuvation Bio Inc. (NUVB): Billionaire David Abrams Has a Long-Term Bet on This Stock [Yahoo! Finance]
Medium
Report
Nuvation Bio Inc. (NUVB): Billionaire David Abrams Has a Long-Term Bet on This Stock [Yahoo! Finance]
3/26
04:43 pm
nuvb
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency [Yahoo! Finance]
Medium
Report
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency [Yahoo! Finance]
3/26
04:05 pm
nuvb
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
Medium
Report
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
3/26
10:00 am
nuvb
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
3/24
05:13 pm
nuvb
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
3/21
05:15 pm
nuvb
NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm
Low
Report
NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law Firm
3/21
11:16 am
nuvb
Is It Time To Reassess Nuvation Bio (NUVB) After Its Recent Share Price Swings [Yahoo! Finance]
Low
Report
Is It Time To Reassess Nuvation Bio (NUVB) After Its Recent Share Price Swings [Yahoo! Finance]
3/19
10:00 am
nuvb
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
3/17
05:33 pm
nuvb
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB
3/17
04:55 pm
nuvb
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026 [Yahoo! Finance]
Low
Report
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026 [Yahoo! Finance]
3/17
04:35 pm
nuvb
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026
Low
Report
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026